ONWARD Medical, an Eindhoven-based NeuroTech company developing therapies aimed at restoring shiftment, function, and indepfinishence for people with spinal cord…
Read More
Stockholm’s BioLamina secures €20 million EIB loan to scale cell therapies for chronic diseases
BioLamina, a Stockholm-based BioTech scale-up specialising in matrix biology and cell culture, has secured a €20 million financing commitment from…
Read More
Utrecht’s Laigo Bio completes final close of €17 million Seed round to advance cancer and autoimmune therapies
Laigo Bio, a Utrecht-based BioTech firm focapplyd on protein degradation for tarreceiveed therapies, has concluded the second close of its…
Read More
NanoZymeX secures €160K to advance lipid nanoparticle enzyme therapies for rare diseases
Biotech startup NanoZymeX has obtained €160,000 (CHF 150,000) from Venture Kick to advance a new platform for enzyme replacement therapy…
Read More
London’s Engitix secures €21 million extension to advance ECM-tarobtained cancer and fibrosis therapies
Engitix, a British BioTech company tarobtaining the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced…
Read More
BioRestorative Therapies Faces Revenue Drop But Keeps Wall Street’s Favor
What’s going on here? BioRestorative Therapies just posted a rough quarter, with much lower revenue and steeper losses – but…
Read More
As millions await approved therapies, myTomorrows strengthens its global patient-access mission with €25 million
myTomorrows, a Dutch HealthTech company that connects patients with possible pre-approval treatments, today announced the close of a €25 million…
Read More
Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies
Leveraging its Accelerator™ Drug Development, 360° CDMO and CMO solutions, Thermo Fisher will provide clinical research services for Lyndra’s phase…
Read More
